Chinese PLA General Hospital Hainan Branch
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 300
- 主要终点
- coronary calcification score
研究概览
简要总结
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
详细描述
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients > 18, < 80 years old, with type 2 diabetes mellitus and coronary heart disease.
排除标准
- •Allergy or hypersensitivity to any of the drug's components. Severe liver failure, moderate or severe kidney failure Malignant disease. Active infectious disease. Pregnancy or breastfeeding.
研究组 & 干预措施
Sitagliptin
干预措施: Sitagliptin (Drug)
CONTROL
Acarbose
干预措施: Acarbose (Drug)
结局指标
主要结局
coronary calcification score
时间窗: Changes from baseline in coronary calcification score at 18 months]
Changes in coronary calcification score in Patients with coronary heart disease complicated with Type 2 Diabetes was measure with Computed tomography angiography. To measure the changes in coronary calcification score at 18 months.
次要结局
未报告次要终点
研究者
Li Bo
Li Bo
Chinese PLA General Hospital